Galmed Pharmaceuticals(GLMD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GLMD Galmed Pharmaceuticals

交易中 10-01 12:13:04 EDT

4.63

+0.00

0.00%

最高4.63	最低4.63	成交量0.00
今开4.63	昨收4.63	日振幅0.00%
总市值482.26万	流通市值467.59万	总股本104.16万
成交额0.00	换手率0.00%	流通股本100.99万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GLMD","market":"US","secType":"STK","nameCN":"Galmed Pharmaceuticals","latestPrice":4.63,"timestamp":1790871184641,"preClose":4.63,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":1009912,"shares":1041600,"eps":-14.105857,"marketStatus":"交易中","change":0,"latestTime":"10-01 12:13:04 EDT","open":4.63,"high":4.63,"low":4.63,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-14.105857,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"symbolChange":{"newSymbol":"EOCN","executeDate":"2026-09-10"},"adr":0,"adrRate":0,"listingDate":1394683200000,"exchange":"NASDAQ","adjPreClose":4.63,"volumeRatio":0,"impliedVol":0.7031,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/GLMD","defaultTab":"news","newsList":[{"id":"1120762135","title":"Galmed宣布Colospan创新术中组织评估技术首个人体概念验证临床研究取得圆满成功","url":"https://stock-news.laohu8.com/highlight/detail?id=1120762135","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120762135?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:01","pubTimestamp":1787137282,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd.今日正式对外宣布，其旗下Colospan部门所研发的突破性术中组织评估技术，已在首个人体概念验证临床研究中斩获成功结果。在此次开创性的人体试验中，研究团队对Colospan的这项新型技术进行了严格而全面的评估。公司管理层对此次试验结果给予了高度评价，认为这不仅是对Colospan技术平台科学价值的有力佐证，更是为全球数百万需要接受手术治疗的患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152964264","title":"Galmed首次公布前列腺癌研究结果：Aramchol在癌细胞死亡效果上较恩杂鲁胺（Xtandi®）单药治疗提升3-4倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1152964264","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152964264?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:16","pubTimestamp":1786972570,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals今日宣布，其前列腺癌研究项目迎来了里程碑式的首次数据披露。实验结果显示，在针对前列腺癌的模型中，Aramchol与恩杂鲁胺联合使用时，癌细胞死亡率较单用恩杂鲁胺实现了令人瞩目的3至4倍提升。Galmed公司强调，这些结果将为后续更深入的临床探索奠定坚实基础，并有望为前列腺癌患者开辟新的治疗路径。业界专家认为，若这一效应能在人体临床试验中得到复现，Aramchol或许能成为联合治疗策略中的关键一环，重塑晚期前列腺癌的治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138308832","title":"Galmed Pharmaceuticals子公司与Yissum签署共同终止函，解除2021年6月28日签署的许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1138308832","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138308832?lang=zh_cn&edition=full","pubTime":"2026-07-30 05:31","pubTimestamp":1785360718,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals（股票代码：GLMD）旗下子公司已与Yissum达成一项共同终止协议，正式废除双方于2021年6月28日签署的许可协议。这一行动通过一份联合终止函得以实现，标志着双方合作关系的正式终结。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159660231","title":"Galmed Pharmaceuticals：子公司资助授权专利持续费用的义务将于7月31日终止","url":"https://stock-news.laohu8.com/highlight/detail?id=1159660231","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159660231?lang=zh_cn&edition=full","pubTime":"2026-07-30 05:20","pubTimestamp":1785360022,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals 宣布，其子公司为授权专利相关的持续性费用提供资金支持的义务，将自7月31日起正式终止。这一重大变化，意味着相关专利费用的财务负担将迎来显著调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148784879","title":"Galmed Pharmaceuticals：因协议终止，授权技术全部权利将归还Yissum","url":"https://stock-news.laohu8.com/highlight/detail?id=1148784879","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148784879?lang=zh_cn&edition=full","pubTime":"2026-07-30 04:54","pubTimestamp":1785358455,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals宣布，由于协议终止，所有与授权技术相关的权利将悉数返还给Yissum。这一决定，标志着双方合作关系的正式终结，同时也意味着相关技术资产的归属权将发生根本性变更。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146815825","title":"Galmed宣布其SCD1抑制剂Aramchol的新型LNP心脏靶向制剂取得突破性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1146815825","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146815825?lang=zh_cn&edition=full","pubTime":"2026-07-16 19:34","pubTimestamp":1784201676,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd. 近日宣布，其在研药物Aramchol——一种硬脂酰辅酶A去饱和酶1（SCD1）抑制剂——的新型脂质纳米颗粒（LNP）心脏靶向制剂开发取得了突破性进展。\n这一创新制剂技术旨在将Aramchol特异性地递送至心脏组织，有望更精准地治疗与心脏代谢相关的疾病，同时可能减少全身性暴露带来的潜在副作用。Aramchol本身作为一种SCD1抑制剂，其作用机制是通过调节脂质代谢来发挥治疗潜力。\n此次宣布的突破性进展标志着Galmed在探索Aramchol新的应用领域和递送方式上迈出了关键一步，可能为满足未竟的医疗需求开辟新的治疗途径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130610943","title":"Galmed制药公司现金支付增加80万美元，并自2027年第三季度起重组200万美元盈利支付条款","url":"https://stock-news.laohu8.com/highlight/detail?id=1130610943","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130610943?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:02","pubTimestamp":1782126134,"startTime":"0","endTime":"0","summary":"Galmed制药公司宣布调整其财务安排，一方面将增加80万美元的现金支付，另一方面，针对一笔200万美元的盈利支付条款进行了重组，新的支付结构计划从2027年第三季度开始生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125493566","title":"Galmed Pharmaceuticals Ltd. 宣布调整对Colospan Ltd.的收购条款，优先推进CG-100欧洲商业化并保护股东价值，完成收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1125493566","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125493566?lang=zh_cn&edition=full","pubTime":"2026-06-22 19:01","pubTimestamp":1782126080,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd. 宣布，已调整对Colospan Ltd.的收购条款，旨在优先推进CG-100在欧洲的商业化进程，并保护公司股东价值。此次收购现已完成。新的条款结构反映了公司战略重点的调整，确保核心资产的价值最大化，同时为未来的市场拓展奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189988467","title":"Galmed制药收购Colospan，股东将获250万美元现金及200万美元公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1189988467","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189988467?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:12","pubTimestamp":1780920749,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd.  宣布完成对Colospan公司的收购，交易方案正式出炉。根据协议，Colospan的股东将在交易完成时获得总计250万美元的现金对价，同时还将获得价值200万美元的Galmed Pharmaceuticals公司普通股股份。此次收购整合了双方的资源与技术，旨在强化Galmed在特定治疗领域的研发管线。市场分析认为，这一交易结构有助于平衡交易各方的风险与回报，并可能为Galmed带来新的增长动力。交易的具体细节与股份折算价格已依据相关协议确定，预计将在交割时执行完毕。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196763236","title":"Galmed Pharmaceuticals将收购Colospan，打造聚焦胃肠疾病、瞄准60亿美元市场的平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1196763236","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196763236?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:12","pubTimestamp":1780920744,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd.（纳斯达克：GLMD）宣布，将收购Colospan公司，旨在整合双方优势，打造一个专注于胃肠疾病（GI）领域的综合平台。此举意在共同瞄准一个规模高达60亿美元的巨大市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157932668","title":"英国MHRA批准Resmetirom（Rezdiffra）用于治疗成人代谢功能障碍相关脂肪性肝炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1157932668","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157932668?lang=zh_cn&edition=full","pubTime":"2026-06-03 23:30","pubTimestamp":1780500616,"startTime":"0","endTime":"0","summary":"英国药品和健康产品管理局已批准Resmetirom（商品名Rezdiffra）用于治疗成人代谢功能障碍相关脂肪性肝炎。这一决定为MASH患者提供了一种新的治疗选择。该药物的获批基于其临床试验中展现出的疗效与安全性数据。MASH是一种严重的肝脏疾病，与代谢功能障碍密切相关，可导致肝纤维化、肝硬化甚至肝癌。新疗法的问世，有望满足该领域长期存在的未满足医疗需求，改善患者临床结局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178617716","title":"Galmed公布Aramchol葡甲胺口服制剂首次人体药代动力学研究结果：400毫克剂量生物利用度较Aramchol游离酸300毫克提升约500%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178617716","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178617716?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:32","pubTimestamp":1778758334,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd. 近日公布了其口服制剂Aramchol葡甲胺（Am）首次人体药代动力学研究的积极数据。研究结果显示，单次口服400毫克剂量的Aramchol葡甲胺，其生物利用度相较于300毫克的Aramchol游离酸（Aa），实现了约500%的显著提升。\n这项研究标志着公司药物开发进程中的一个重要里程碑。生物利用度的大幅提高，意味着患者未来可能以更低的剂量达到预期的治疗效果，或在使用相同剂量时获得更强的药效，这为后续的临床开发奠定了坚实的药理学基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153278866","title":"Tissue Dynamics与Galmed制药将合作开发以人为中心的慢性心脏纤维化平台 推进基于Aramchol的疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1153278866","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153278866?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:35","pubTimestamp":1778067309,"startTime":"0","endTime":"0","summary":"Tissue Dynamics公司与Galmed制药有限公司（纳斯达克代码：GLMD）宣布达成战略合作，将共同构建专注于人类疾病模型的慢性心脏纤维化研究平台。该合作旨在加速基于Aramchol（Galmed公司核心候选药物）的新型治疗方案开发进程。\n此次合作将结合Tissue Dynamics在人体组织动态监测领域的专长与Galmed在代谢性疾病治疗药物研发方面的经验，重点关注心脏纤维化这一影响全球数百万患者的慢性疾病领域。通过建立更贴近人类病理生理特征的实验平台，双方期望提升药物研发效率，为心血管疾病患者提供更精准的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187957944","title":"Galmed与特拉维夫大学达成合作，评估Scd1抑制剂Aramchol作为转移性脑癌靶向疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1187957944","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187957944?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:30","pubTimestamp":1776166246,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd.（纳斯达克代码：GLMD）近日宣布与以色列特拉维夫大学签署一项合作协议，双方将共同研究其开发的硬脂酰辅酶A去饱和酶1（Scd1）抑制剂Aramchol在转移性脑癌治疗领域的靶向应用潜力。该合作旨在通过临床前模型验证Aramchol调节肿瘤代谢通路的作用机制，探索其对血脑屏障的穿透性及抑制癌细胞转移的效果。若研究取得积极成果，这款原本用于非酒精性脂肪性肝炎治疗的药物或将为晚期脑癌患者提供新的治疗方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518627588","title":"Galmed Pharmaceuticals Ltd.盘中异动 早盘股价大涨5.41%报1.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518627588","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518627588?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:08","pubTimestamp":1741615689,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时08分，Galmed Pharmaceuticals Ltd.股票出现波动，股价大幅上涨5.41%。截至发稿，该股报1.99美元/股，成交量3880股，换手率0.23%，振幅1.98%。Galmed Pharmaceuticals Ltd.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3195.32%、693.14%、99.01%，振幅较大的相关个股有Scisparc Ltd.、Pmgc Holdings Inc.、Impact Biomedical, Inc.，振幅分别为40.24%、32.14%、28.59%。Galmed Pharmaceuticals Ltd.公司简介：Galmed Pharmaceuticals Ltd是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220809abf30a5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220809abf30a5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517390943","title":"Galmed Pharmaceuticals Ltd.盘中异动 早盘股价大跌6.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517390943","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517390943?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:33","pubTimestamp":1741185231,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时33分，Galmed Pharmaceuticals Ltd.股票出现异动，股价快速跳水6.38%。截至发稿，该股报1.81美元/股，成交量1478股，换手率0.09%，振幅0.00%。Galmed Pharmaceuticals Ltd.股票所在的生物技术行业中，整体涨幅为0.26%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Zyversa Therapeutics, Inc.较为活跃，换手率分别为366.52%、259.94%、187.55%，振幅较大的相关个股有Aditxt, Inc.、Silexion Therapeutics Corp、Invivyd, Inc.，振幅分别为23.90%、16.21%、13.32%。Galmed Pharmaceuticals Ltd.公司简介：Galmed Pharmaceuticals Ltd是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223352963adce3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223352963adce3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516608715","title":"Galmed Pharmaceuticals Ltd.盘中异动 快速跳水5.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608715","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516608715?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:25","pubTimestamp":1741101909,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时25分，Galmed Pharmaceuticals Ltd.股票出现波动，股价大幅下挫5.67%。Galmed Pharmaceuticals Ltd.股票所在的生物技术行业中，整体涨幅为0.32%。其相关个股中，Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1174.66%、1135.91%、688.61%，振幅较大的相关个股有Nkgen Biotech Inc C/Wts 31/05/2028、Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 ，振幅分别为100.00%、68.71%、66.67%。Galmed Pharmaceuticals Ltd.公司简介：Galmed Pharmaceuticals Ltd是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232510abe7ff7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232510abe7ff7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516658722","title":"Galmed Pharmaceuticals Ltd.盘中异动 股价大跌7.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658722","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516658722?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:50","pubTimestamp":1741017022,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时50分，Galmed Pharmaceuticals Ltd.股票出现波动，股价快速下挫7.01%。截至发稿，该股报1.99美元/股，成交量7049股，换手率0.43%，振幅13.55%。Galmed Pharmaceuticals Ltd.股票所在的生物技术行业中，整体跌幅为0.43%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Aldeyra Therapeutics, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为2829.50%、140.99%、133.14%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为206.20%、70.53%、50.09%。Galmed Pharmaceuticals Ltd.公司简介：Galmed Pharmaceuticals Ltd是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303235022989a23b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303235022989a23b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514233263","title":"Galmed Pharmaceuticals Ltd.盘中异动 股价大跌7.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514233263","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514233263?lang=zh_cn&edition=full","pubTime":"2025-02-28 04:20","pubTimestamp":1740687623,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日04时20分，Galmed Pharmaceuticals Ltd.股票出现波动，股价快速下跌7.39%。截至发稿，该股报2.13美元/股，成交量1.5976万股，换手率0.96%，振幅7.39%。Galmed Pharmaceuticals Ltd.股票所在的生物技术行业中，整体跌幅为0.39%。其相关个股中，Pepgen Inc.、Ibio, Inc.、Xortx Therapeutics Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Vincerx Pharma, Inc.较为活跃，换手率分别为1923.58%、364.70%、192.31%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pepgen Inc.、Pds Biotechnology Corporation，振幅分别为86.14%、67.32%、55.84%。Galmed Pharmaceuticals Ltd.公司简介：Galmed Pharmaceuticals Ltd是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228042024abdfbaa5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228042024abdfbaa5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514016024","title":"Galmed Pharmaceuticals Ltd.盘中异动 股价大跌5.09%报2.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514016024","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514016024?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:46","pubTimestamp":1740498409,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时46分，Galmed Pharmaceuticals Ltd.股票出现异动，股价大幅下跌5.09%。截至发稿，该股报2.61美元/股，成交量5908股，换手率0.36%，振幅8.36%。Galmed Pharmaceuticals Ltd.股票所在的生物技术行业中，整体涨幅为0.86%。其相关个股中，Silexion Therapeutics Corp、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Abpro Holdings Inc C/Wts 12/11/2029 涨幅较大，Gt Biopharma, Inc.、Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为1090.93%、604.71%、568.48%，振幅较大的相关个股有Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 ，振幅分别为64.05%、61.16%、60.87%。Galmed Pharmaceuticals Ltd.公司简介：Galmed Pharmaceuticals Ltd是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225234649abdc90bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225234649abdc90bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.galmedpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.1238},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0718},{"period":"1year","weight":-0.5806},{"period":"ytd","weight":-0.2288}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Galmed Pharmaceuticals Ltd.于2013年7月31日在以色列注册成立，是一家以色列私营公司。该公司目前正致力于推进Aramchol的研发，用于治疗胃肠道肿瘤的联合疗法。作为其增长战略的一部分，该公司积极寻求生物技术和医疗技术领域的机遇，以拓展和丰富其产品线，尤其关注胃肠道和心血管代谢疾病，以及其他符合其核心竞争力的创新候选产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.024695},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.055437},{"month":3,"riseRate":0.25,"avgChangeRate":-0.083341},{"month":4,"riseRate":0.538462,"avgChangeRate":-0.000255},{"month":5,"riseRate":0.461538,"avgChangeRate":-0.058128},{"month":6,"riseRate":0.692308,"avgChangeRate":0.128295},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.078327},{"month":8,"riseRate":0.230769,"avgChangeRate":-0.066784},{"month":9,"riseRate":0.538462,"avgChangeRate":0.041656},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.138105},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.048693},{"month":12,"riseRate":0.416667,"avgChangeRate":0.037621}],"exchange":"NASDAQ","name":"Galmed Pharmaceuticals","nameEN":"Galmed Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Galmed Pharmaceuticals(GLMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Galmed Pharmaceuticals(GLMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Galmed Pharmaceuticals,GLMD,Galmed Pharmaceuticals股票,Galmed Pharmaceuticals股票老虎,Galmed Pharmaceuticals股票老虎国际,Galmed Pharmaceuticals行情,Galmed Pharmaceuticals股票行情,Galmed Pharmaceuticals股价,Galmed Pharmaceuticals股市,Galmed Pharmaceuticals股票价格,Galmed Pharmaceuticals股票交易,Galmed Pharmaceuticals股票购买,Galmed Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Galmed Pharmaceuticals(GLMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Galmed Pharmaceuticals(GLMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}